Marker Therapeutics
MRKR
28 hedge funds and large institutions have $10.9M invested in Marker Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
28% more capital invested
Capital invested by funds: $8.52M → $10.9M (+$2.38M)
0.25% more ownership
Funds ownership: 22.27% → 22.52% (+0.25%)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$102K |
| 2 |
BlackRock
New York
|
+$42.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.6K |
| 4 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$8.5K |
| 5 |
Renaissance Technologies
New York
|
+$6.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$63.7K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$6.37K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$6.13K |
| 4 |
Morgan Stanley
New York
|
-$2.69K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.84K |
MRKR Hedge Fund Activity: Q2 2024 in Review
28 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2024, worth a combined $10.9M — up 28% from $8.52M a quarter earlier.
Fund positioning in MRKR was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 4 trimmed.
The largest buyer was Wedbush Securities, adding an estimated $102K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $63.7K sold.
- 28 institutional investors held Marker Therapeutics (MRKR) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $10.9M of Marker Therapeutics stock for Q2 2024, up 28% quarter-over-quarter.
- 2 funds opened new Marker Therapeutics positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Marker Therapeutics buyer in Q2 2024 was Wedbush Securities, an estimated $102K added.
- The largest Marker Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $63.7K sold.
Based on aggregated 13F filings for Q2 2024.